Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-month Follow-up Study

Çolak N. D., Karabağg T., Çalışkan O., TEZCAN S.

Journal of the Saudi Heart Association, cilt.38, sa.1, 2026 (ESCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.37616/2212-5043.1478
  • Dergi Adı: Journal of the Saudi Heart Association
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: Acute coronary syndrome, Biomarker, Carbohydrate antigen 125, Cardiovascular diseases, Major cardiac adverse events
  • Marmara Üniversitesi Adresli: Evet

Özet

Objectives: Carbohydrate antigen 125 (CA125) is associated with different cardiovascular conditions. This study aimed to determine CA125 levels in patients with acute coronary syndrome (ACS) and the potential relationship between major adverse cardiac events (MACE) in the short-term following. Methods: This prospective cohort study was conducted in a coronary care unit between May and November 2022. Plasma CA125 levels were measured only once upon hospital admission. Patients were followed for six months. All-cause mortality, recurrent acute coronary syndrome, requirement for revascularization, decompensated heart failure, cardiogenic pulmonary edema, atrial fibrillation, and stroke were recorded as MACE. Results: A total of 127 patients were included in this study. The mean left ventricular ejection fraction (LVEF) was 50.5 %. The median plasma CA125 level was 14.6 KU/L. There was a, significant positive relationship between CA125 and high-sensitivity cardiac troponin (hs-cTn) (r ¼ 0.315, p < 0.001) and pro—B-type natriuretic peptide (proBNP) (r ¼ 0.423, p < 0.001), and a weak negative relationship with LVEF (r ¼ ¡0.186, p ¼ 0.037) value. Conclusions: Plasma CA125 levels were correlated with the pro-BNP and hs-cTn, established ACS biomarkers. An additional notable finding was the weak correlation with LVEF. Elevated plasma CA125 levels might be used to identify patients with ACS who are at higher risk of MACE at six months.